Sailing on in Sanfilippo

What positive data for AMT-110 in Sanfilippo B patients means for uniQure

uniQure N.V. says Phase I/II data on AMT-110 support both the start of a pivotal trial for Sanfilippo type B syndrome, and the company's plans to use its AAV5 vector in other rare lysosomal storage disorders with a CNS component.

AMT-110 uses an adeno-associated virus 5 (AAV5) vector to deliver the N-acetylglucosaminidase alpha (NAGLU) gene to the CNS via intracerebral injection.

Mutations in NAGLU cause Sanfilippo type B, also called mucopolysaccharidosis IIIB (MPS IIIB). Patients with MPS IIIB are unable to degrade heparan sulfate glycosaminoglycans (HSGAGs), which accumulate in the lysosome. The clinical manifestations of the disease are mainly neurological and include behavior and sleep disorders, communication problems and intellectual deterioration. As it progresses, patients

Read the full 1163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers